As Chief Scientific Officer, Dr. Lesley Northrop leads Product Innovation and Research and Development activities as they translate to clinical diagnostic test development. Dr. Northrop has been working in molecular genetics for 20 years in academic research labs, private and large hospital clinical practices and genetic commercial companies predominately focused on female reproductive health. At Aspira Women’s Health Dr. Northrop is focused on building and leading a team of highly skilled individuals able to support the business in its ambitious goals. Dr. Northrop is responsible for overall business innovation and proactively explores new technologies.
Dr. Northrop specializes in developing new technology as it translates from research to a clinical diagnostic test. She has built 4 brand-new clinical molecular genetics laboratories for NYS CLIA/CAP- accreditation during her career and is an expert in LDT design and validation predominately using NGS technologies. She also has extensive expertise in developing clinical assays for commercial offerings.
She also serves as a Laboratory Director of Aspira’s Molecular Genetics Laboratory, holds a NYS CQ in molecular genetics and CA-CPDH and NJ Bioanalysis Director license. She obtained her MSc/Ph.D. from Boston University and conducted her American Board of Genomics and Genetics Fellowship (ABMGG) training at Columbia University in Clinical Cytogenetics and Molecular Genetics. She is boarded and a fellow of ABMGG in Molecular Genetics.
Prior to joining Aspira Women’s Health Dr. Northrop was SVP of Clinical Genetics and Clinical Molecular Genetics Laboratory Director with Celmatix. She also was also formerly Clinical Molecular Genetics Laboratory Director at Fresenius Medical Care North America. Dr. Northrop began her journey working on species survival of endangered animals all over the world primarily in captive and wild Giant and Red Pandas. She then entered into the human infertility field as her first post-doctoral fellow to help build a clinical molecular genetics lab at one of the largest IVF centers in the country (RMA-NJ). During that time, she helped develop single cell-based technologies for the detection of aneuploidy, translocations, and implementation of monogenic disorder screening in preimplantation embryos. This changed the face of IVF technology for preimplantation genetic testing (PGT) to a more comprehensive method with higher sensitivity and specificity.